Pharmacological inhibition of PDE2A in animal models has been shown to have beneficial effects in a number of conditions, such as cardiac hypertrophy (Zoccarato et al., 2015), pulmonary hypertension (Bubb et al., 2014) as well as depression, anxiety and cognition deficits in Alzheimer’s disease (Zhang et al., 2015). This evidence concerns the gene PDE2A and early-onset autosomal dominant Alzheimer disease.